StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.
VNRX has been the subject of a number of other reports. Benchmark restated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a report on Wednesday.
Check Out Our Latest Stock Report on VolitionRx
VolitionRx Price Performance
Insider Activity at VolitionRx
In other news, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Cameron John Reynolds bought 139,811 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 358,266 shares of company stock worth $204,212. Corporate insiders own 12.80% of the company’s stock.
Institutional Investors Weigh In On VolitionRx
An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its holdings in shares of VolitionRx Limited (NYSE:VNRX – Free Report) by 78.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by institutional investors and hedge funds.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Read More
- Five stocks we like better than VolitionRx
- How to Buy Cheap Stocks Step by Step
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Stock Analyst Ratings and Canadian Analyst Ratings
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.